Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
DrugDrug NameDrug Indication
DB00017Salmon CalcitoninUsed in the treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments. In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified. It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause.
DB00136CalcitriolUsed to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.
DB00146CalcidiolUsed to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.
DB00153ErgocalciferolFor use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).
DB00169CholecalciferolFor the treatment of vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.
DB00282PamidronateFor the treatment of moderate or severe hypercalcemia associated with malignancy
DB00399Zoledronic acidFor the treatment of hypercalcemia of malignancy. Also for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. In May of 2007, the drug was approved for treatment of Paget’s Disease.
DB00481RaloxifeneFor the prevention and treatment of osteoporosis in post-menopausal women, as well as prevention and treatment of corticosteroid-induced bone loss. Also for the reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis or have a high risk for developing breast cancer.
DB00539ToremifeneFor the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.
DB00630Alendronic acidFor the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
DB00675TamoxifenTamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ.
DB00710IbandronateFor the treatment and prevention of osteoporosis in postmenopausal women.
DB00720Clodronic AcidFor the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors.
DB00884RisedronateFor the treatment of Paget's disease of the bone (osteitis deformans), postmenopausal and glucocorticoid-induced osteoporosis
DB00910ParicalcitolFor treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
DB01070DihydrotachysterolUsed for the prevention and treatment of rickets or osteomalacia, and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism. Also used for the treatment of vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).
DB01077Etidronic acidFor the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.
DB01133Tiludronic acidFor treatment of Paget's disease of bone (osteitis deformans).
DB01436AlfacalcidolAlfacalcidol is an active metabolite of Vitamin D, which performs important functions in regulation of the calcium balance and the bone metabolism.
DB06255Incadronic acidFor the treatment of hypercalcemia associated with malignant disease.
DB06285TeriparatideFor the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
DB06401BazedoxifeneInvestigated for use/treatment in osteoporosis and menopause.
DB06410DoxercalciferolDoxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease.
DB06643DenosumabProlia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass. Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
DB09267Strontium ranelateFor the treatment of osteoporosis.
DrugDrug NameTargetType
DB00017Salmon CalcitoninCalcitonin receptortarget
DB00136CalcitriolVitamin D3 receptortarget
DB00136Calcitriol1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrialenzyme
DB00136CalcitriolCytochrome P450 3A4enzyme
DB00146Calcidiol25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrialenzyme
DB00146CalcidiolVitamin D3 receptortarget
DB00146Calcidiol1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrialenzyme
DB00153ErgocalciferolVitamin D3 receptortarget
DB00153Ergocalciferol1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrialenzyme
DB00153Ergocalciferol25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrialenzyme
DB00153ErgocalciferolSterol 26-hydroxylase, mitochondrialenzyme
DB00153ErgocalciferolCytochrome P450 3A4enzyme
DB00153ErgocalciferolVitamin D 25-hydroxylaseenzyme
DB00169CholecalciferolVitamin D-binding proteincarrier
DB00169CholecalciferolCholesterol side-chain cleavage enzyme, mitochondrialenzyme
DB00169CholecalciferolVitamin D 25-hydroxylaseenzyme
DB00169CholecalciferolSterol 26-hydroxylase, mitochondrialenzyme
DB00169CholecalciferolCytochrome P450 2J2enzyme
DB00169CholecalciferolCytochrome P450 3A4enzyme
DB00169CholecalciferolVitamin D3 receptortarget
DB00169CholecalciferolCytochrome P450 1A1enzyme
DB00169CholecalciferolCytochrome P450 2B6enzyme
DB00169CholecalciferolCytochrome P450 2C19enzyme
DB00169CholecalciferolCytochrome P450 2C8enzyme
DB00169CholecalciferolCytochrome P450 2C9enzyme
DB00169CholecalciferolCytochrome P450 2D6enzyme
DB00282PamidronateFarnesyl pyrophosphate synthasetarget
DB00282PamidronateHydroxylapatitetarget
DB00399Zoledronic acidFarnesyl pyrophosphate synthasetarget
DB00399Zoledronic acidGeranylgeranyl pyrophosphate synthasetarget
DB00399Zoledronic acidHydroxylapatitetarget
DB00399Zoledronic acidMultidrug resistance-associated protein 1transporter
DB00481RaloxifeneEstrogen receptortarget
DB00481RaloxifeneEstrogen receptor betatarget
DB00481RaloxifeneAldehyde oxidaseenzyme
DB00481RaloxifeneCytochrome P450 2C8enzyme
DB00481RaloxifeneCytochrome P450 2B6enzyme
DB00481RaloxifeneCytochrome P450 19A1enzyme
DB00481RaloxifeneCytochrome P450 3A4enzyme
DB00539ToremifeneEstrogen receptortarget
DB00539ToremifeneCytochrome P450 3A4enzyme
DB00539ToremifeneMultidrug resistance protein 1transporter
DB00539ToremifeneCytochrome P450 1A1enzyme
DB00539ToremifeneCytochrome P450 1A2enzyme
DB00630Alendronic acidFarnesyl pyrophosphate synthasetarget
DB00630Alendronic acidTyrosine-protein phosphatase non-receptor type 4target
DB00630Alendronic acidReceptor-type tyrosine-protein phosphatase Starget
DB00630Alendronic acidReceptor-type tyrosine-protein phosphatase epsilontarget
DB00630Alendronic acidV-type proton ATPase catalytic subunit Atarget
DB00630Alendronic acidHydroxylapatitetarget
DB00675TamoxifenEstrogen receptortarget
DB00675TamoxifenEstrogen receptor betatarget
DB00675TamoxifenCytochrome P450 2C9enzyme
DB00675TamoxifenCytochrome P450 3A4enzyme
DB00675TamoxifenCytochrome P450 2D6enzyme
DB00675TamoxifenCytochrome P450 2C8enzyme
DB00675TamoxifenCytochrome P450 2B6enzyme
DB00675TamoxifenLiver carboxylesterase 1enzyme
DB00675TamoxifenCytochrome P450 3A5enzyme
DB00675TamoxifenCytochrome P450 1A1enzyme
DB00675TamoxifenCytochrome P450 1A2enzyme
DB00675TamoxifenCytochrome P450 1B1enzyme
DB00675TamoxifenCytochrome P450 2C19enzyme
DB00675TamoxifenDimethylaniline monooxygenase [N-oxide-forming] 1enzyme
DB00675TamoxifenDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00675TamoxifenCytochrome P450 3A7enzyme
DB00675TamoxifenMultidrug resistance protein 1transporter
DB00675TamoxifenBile salt export pumptransporter
DB00675TamoxifenATP-binding cassette sub-family G member 2transporter
DB00675TamoxifenCytochrome P450 19A1enzyme
DB00675TamoxifenCytochrome P450 2A6enzyme
DB00675TamoxifenCytochrome P450 2E1enzyme
DB00675TamoxifenUDP-glucuronosyltransferase 1-4enzyme
DB00675TamoxifenSulfotransferase 1A1enzyme
DB00675TamoxifenCanalicular multispecific organic anion transporter 1transporter
DB00675Tamoxifen3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerasetarget
DB00675TamoxifenProtein kinase Ctarget
DB00710IbandronateFarnesyl pyrophosphate synthasetarget
DB00710IbandronateHydroxylapatitetarget
DB00720Clodronic AcidADP/ATP translocase 2target
DB00720Clodronic AcidADP/ATP translocase 1target
DB00720Clodronic AcidADP/ATP translocase 3target
DB00720Clodronic AcidHydroxylapatitetarget
DB00720Clodronic AcidProstaglandin G/H synthase 2enzyme
DB00884RisedronateFarnesyl pyrophosphate synthasetarget
DB00884RisedronateHydroxylapatitetarget
DB00884RisedronateProstaglandin G/H synthase 2enzyme
DB00910ParicalcitolVitamin D3 receptortarget
DB00910Paricalcitol1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrialenzyme
DB00910ParicalcitolCytochrome P450 3A4enzyme
DB00910ParicalcitolUDP-glucuronosyltransferase 1-4enzyme
DB01070DihydrotachysterolVitamin D3 receptortarget
DB01077Etidronic acidHydroxylapatitetarget
DB01077Etidronic acidReceptor-type tyrosine-protein phosphatase Starget
DB01077Etidronic acidV-type proton ATPase catalytic subunit Atarget
DB01077Etidronic acidAdenosine triphosphate (ATP)target
DB01133Tiludronic acidTyrosine-protein phosphatase non-receptor type 1target
DB01133Tiludronic acidV-type proton ATPase catalytic subunit Atarget
DB01133Tiludronic acidHydroxylapatitetarget
DB01133Tiludronic acidAdenosine triphosphate (ATP)target
DB01436AlfacalcidolVitamin D-binding proteincarrier
DB01436AlfacalcidolVitamin D3 receptortarget
DB01436Alfacalcidol25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrialtarget
DB06285TeriparatideParathyroid hormone/parathyroid hormone-related peptide receptortarget
DB06401BazedoxifeneEstrogen receptortarget
DB06401BazedoxifeneUDP-glucuronosyltransferase 1A1enzyme
DB06410DoxercalciferolSterol 26-hydroxylase, mitochondrialenzyme
DB06410DoxercalciferolVitamin D3 receptortarget
DB06643DenosumabTumor necrosis factor ligand superfamily member 11target